Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension

American Journal of Cardiology

Volumn 92, Issue 1, 2003, Pages 38-42

  White, William B ^a   Carr, Albert A ^b   Krause, Scott ^b   Jordan, Rosanne ^b   Roniker, Barbara ^b   Oigman, Wille ^b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; EPLERENONE; POTASSIUM; RENIN;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; GYNECOMASTIA; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MENSTRUATION DISORDER; MULTICENTER STUDY; PAIN; PARALLEL DESIGN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION;

EID: 0037861923     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00461-2     Document Type: Article

References (10)

1. Coats A.J. Exciting new drugs on the horizon - eplerenone, a selective aldosterone receptor antagonist. Int J Cardiol. 80:2001;1-4.
2. Delyani J.A., Rocha R., Cook C.S., Tolbert D.S., Levin S., Roniker B. Eplerenone, a selective aldosterone receptor antagonist. Cardiovasc Drug Rev. 19:2001;185-200.
3. Weinberger M., Roniker B., Krause S.L., Weiss R.J. Eplerenone, a selective aldosterone blocker, in mild to moderate hypertension. Am J Hypertens. 15:2002;709-713.
4. White W.B. Advances in ambulatory blood pressure monitoring for the evaluation of antihypertensive therapy in research and practice. White W.B. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics. 2000;273-298 Humana Press, Totowa, NJ.
5. Mansoor G.A., McCabe E.J., White W.B. Long-term reproducibility of ambulatory blood pressure. J Hypertens. 12:1994;703-708.
6. Coats A.J.S., Radaelli A., Clark S.J., Conway J., Sleight P. The influence of ambulatory blood pressure monitoring on the design and interpretation of trials in hypertension. J Hypertens. 10:1992;385-391.
7. White W.B., Lessem J., Schusterman N. Evaluation of the angiotensin II receptor antagonist, eprosartan, by casual and ambulatory blood pressure. Blood Press Monit. 1:1996;45-51.
8. White W.B. Clinical relevance of ambulatory versus clinic blood pressure when evaluating antihypertensive therapy. Review-in-Depth. Blood Pressure Monit. 1:1996;170-173.
9. White W.B., Sica D.A., Calhoun D., Mansoor G.A., Anders R. Preventing increases in the early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. Am Heart J. 144:2002;657-665.
10. Jeunemaitre X., Charru A., Chatellier G., Degoulet P., Julien J., Plouin P.F., Corvol P., Menard J. Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for the treatment of essential hypertension. Am J Cardiol. 62:1998;1072-1077.